Research Centre Lead
Dr Julie Bennett
Research Project Manager and PA
Tel: +44 (0)20 7679 6803
Amongst all cancers in women, 47% are specific to women (ovarian, uterine, cervical and breast cancers).
Among this group of diseases are those cancers, which are the most aggressive and difficult to treat and which have the highest mortality including basal-like (triple-negative) breast, high grade serous ovarian and serous-like and clear-cell endometrial cancers.
Survival rates for these cancers have largely stagnated in the last few decades despite considerable effort to tangibly improve them.
The single exception and role model that reflects previous endeavours is cervical cancer and the following 4 strategies - in the event that all women opt for vaccination and screening – would make it possible to eradicate cervical cancer completely:
- Understanding: The causative agent is known (i.e. infection with the HPV virus).
- Prediction: The presence of the causative agent can be assessed directly at the area where the cancer arises (i.e. the so called transformation zone of the cervix).
- Prevention: Vaccines against the HPV virus can protect from the infection.
- Early Detection: Early signs of pre-cancers (i.e. abnormal cytological smear) can be easily assessed.
None of the above has been established for the other three women specific cancers and therefore our entire focus in the next 20 years will be directed towards achieving for ovarian, uterine and breast cancer what has already been achieved for cervical cancer.
The four core programmes are:
Epigenetics – Lay Version
Epigenetics literally means ‘upon’ genetics and describes a series of biological processes that affect how our genes behave. Epigenetic processes play a vital role in early and healthy development and are responsible for the cellular diversity throughout our bodies, i.e. whilst all of our cells possess an identical genetic code they both appear and function differently, e.g. our cells in our skin look different and perform a different purpose to those in our bones. This is possible because epigenetic mechanisms turn specific sets of genes ‘on’ and ‘off’ and this determines the cell type. Genes – stretches of DNA that encode a specific protein – are switched ‘on’ and ‘off’ through epigenetic control of gene accessibility, e.g. genes within exposed areas of DNA are considered active (switched ‘on’) whilst those in more densely compacted regions are considered to be inactive (‘switched off’). Epigenetics is therefore important in maintaining health but can become deregulated in diseases including cancer. Click here for a video explaining the concept of epigenetics and cancer.
Epigenetic mechanisms are collectively referred to as the ‘epigenome’ and include one of the best studied epigenetic processes called, ‘DNA methylation’. DNA methylation has been shown to be dramatically altered in cancer tissue and can often be found in normal tissue in areas adjacent to cancer. Furthermore epigenetic mechanisms are responsive to our environment which in turn affects our risk to develop cancer and other disease. Our environmental exposures during development in the womb and after birth, as well as our diet and lifestyle all affect our cancer risk (See Figure 1). Accumulation of epigenetic changes as we age could therefore explain the vast majority of cancer that occurs in women who do not carry a predisposing genetic mutation and furthermore represent valuable biomarkers for disease risk.
Epigenetics provides an explanation for differences in susceptibility to disease between monozygotic twins or cloned animals despite identical DNA sequences. In eukaryotic cells epigenetic modifications are encoded via two primary modes which differ dramatically in their information content: Histone modification and DNA methylation (DNAm). The process of DNAm involves the addition of a methylation group to the fifth carbon of the cytosine ring to form 5-methylcytosine (5meC). Methylation of cytosine occurs when the base precedes a guanosine in the DNA sequence. These ‘CpG dinucleotides’ are uncommon in the vertebrate genome except in small stretches of DNA termed CpG islands, usually 500 to 2,000 base pairs in length, that are frequently located in and around the transcription start sites of genes. Methylation of these CpG islands is usually associated with silencing of the respective gene.
Over the past few years the epigenetic landscape has become extensively studied and more detailed definitions established. CpG island ‘shores’ have been described (CpG clusters that occur outside and up to 2Kb of CpG islands) and have been shown to be important in tissue specific gene expression but also differential methylation occurring in cancer. The tissue specific nature of DNA methylation means that methylation analyses using samples from established biobanks, i.e. whole blood collections would be ineffective owing to cellular heterogeneity of white blood cell types. Consequently, novel prospective tissue specific collections (EPIFEMPRO and EPIFEMGEN) are required to facilitate the optimal discovery of cancer specific differentially methylated regions (DMRs) for clinical development.
The Epigenetic Stem Cell Model of Cancer
In 2007, we and others, published evidence for an ‘epigenetic stem cell model’ of cancer. Embryonic stem cells rely on Polycomb group (PcG) proteins to reversibly repress genes required for differentiation. On cellular differentiation specific gene sets are re-expressed after removal of the PcG proteins from these genes.
We reported (Widschwendter et al Nature Genetics 2007) that stem cell Polycomb group targets are up to 12-fold more likely to have cancer-specific promoter DNA hypermethylation than non-targets (See Figure 1), supporting a stem cell origin of cancer in which reversible gene repression is replaced by permanent silencing as a consequence of this acquired DNA methylation. The model further suggests that as a result of this permanent silencing the stem cell persistently self-replicates owing to an inability to differentiate increasing the risk of subsequent malignant transformation. The observation of an overlap of cancer specific differential methylation and tissue specific methylation at CpG island shores further supports this model.
EFI-FEM (Epigenetics and Female Cancer) Research Programmes
EPIFEMCARE - Epigenetics For Female Personalised Cancer Care. EPIFEMCARE is funded by the EU FP7 programme and is an academic-industrial collaboration that aims to develop new methods for screening, diagnosis and personalised treatment of breast and ovarian cancers.
EPIFEMPRO - EpiFemPro (Epigenetics for Female Malignancies – Prediction of Risk programme) is focused on the discovery of epigenetic biomarkers that determine a woman’s risk to develop a women specific cancer.
EPIFEMGEN - EpiFemGen (Epigenetics of Female Malignancies with Genetic Predisposition): This element of the EpiFem programme involves the study of hormonal, genetic and epigenetic changes in cells and body fluids of women who are known to be genetically predisposed to breast, ovarian and womb/uterine cancers.
Prof Martin Widschwendter
Head of Research Department of Women's Cancer
Consultant Gynaecological Oncologist
Ms Allison Jones
Tel: 020 3108 2001
Further details: I completed my BSc in Applied and Human Biology at Aston University Birmingham in 1997. Since my degree, I have accrued over 17 years’ experience working in cancer research laboratories within London. From 2000 to 2003 I worked at Breakthrough Breast Cancer where I began to specialise in research focussed on understanding the development of women specific cancer and treatment resistance. I joined Professor Widschwendter’s laboratory at UCL in 2006 and have since been integrally involved in two major research programmes: EpiFemCare (an FP7 funded programme of research aiming to develop epigenetic based tests for the early detection of breast and ovarian cancers) and, more recently, FORECEE (a Horizon 2020 programme of research aiming to develop clinical tests to risk predict future development of women specific cancer). As well as undertaking research, my primary role in the team has been to lead on the laboratory logistics required to implement our EC funded research programmes and to project manage timelines. Our research has a primary focus on the study of epigenetics and the involvement of epigenetic processes in cancer development. I am particularly interested in the study of epigenetic changes occurring in normal (non-diseased) cells in response to environmental exposures (e.g. diet, lifestyle) and how these changes could be used to assess an individual’s disease risk.
Dr Gioia Altobelli PhD
Senior Research Associate Bioinformatics, Women’s Cancer
Tel: 020 7679 6063
Further details: A computational biologist experienced in omics data analysis, I am keen on developing integrative computational statistical frameworks that enable reliable exploitation of large-scale, experimental datasets for understanding complex diseases. Corresponding author in epigenomics and bioinformatics, I joined the team in order to assess the association between multi-tissue methylome and multi-cancer risk in FORECEE.
I earned my PhD with a thesis in bioinformatics applied to molecular oncology (breast cancer) at the International School for Advanced Studies at the University of Turin. My background education encompassed physics, biophysics, and computer simulation. I contributed to the understanding of diverse biological systems and processes in a multidisciplinary fashion, authoring 15 peer-reviewed publications (as part of a team as well as independently). Manuscripts in life course epidemiology are in preparation.
Dr Kantaraja Chindera
Tel: 020 3108 2008
Further details: I graduated in Veterinary Medicine in 2004, from the Veterinary College, Bangalore, India. I then completed my Master of Veterinary Science in Animal Biotechnology in 2008 from the Indian Veterinary Research Institute. I secured Commonwealth Scholarships in 2009 to pursue my PhD at The Royal Veterinary College, University of London. During my PhD, I invented a new class of drug delivery molecules and based on these findings, I co-founded a spin out company Tecrea Limited.
Upon completion of my PhD, I joined Prof Widschwendter’s research team. I am actively involved in the BRCA PREVENT project and am investigating the molecular pathways leading to Serous Tubal Intraepithelial Carcinoma (STIC) at the fimbrial end of the Fallopian Tube in BRCA mutation carriers using Fallopian Tube Organoid Models. I am also working on a project which aims to devise preventive measures that could block the appearance of STIC lesions, eventually preventing High Grade Serous Ovarian Cancer. I am actively collaborating with Prof Satish Awasthi, Delhi University to develop evidence based preventive and therapeutic measures to women at high risk of HGSOC. I also mentor MSc student research projects. Our overarching goal is to devise evidence based non-invasive preventive measures for population at high risk of developing High Grade Serous Ovarian Cancer.
Dr Iona Evans
Tel: 020 3108 2001
Further details: Following the completion of a BSc (Hons) degree in Microbiology at the University of Wales, Cardiff in 1999, I went on to do a PhD, investigating the NF-kB pathway and inflammation at University of Sheffield. In September 2004, I made the move to UCL, and started my postdoctoral training, at the Centre for Respiratory Research (later renamed the Centre for Inflammation and Tissue Repair), under the supervision of Prof Robin McAnulty. The main focus of the group was the pathogenesis of inflammatory diseases including pulmonary fibrosis. During this time, I developed an interest in epigenetics, and began to investigate a role for epigenetics in fibroproliferative disease. In 2013, I joined Prof Martin Widschwendter’s team, where epigenetics is the main focus, and began working on the EU funded EpiFemCare project. My focus on this project was the development of a cfDNA based assays to predict breast and ovarian cancer early, using DNA methylation. The team is now working on a very exciting new H2020 project called FORECEE, where we are aiming to develop a screen to predict women’s cancers, using a multi-omics approach.
Mrs Shohreh (Taraneh) Ghazali
Clinical Research Practitioner
Tel: 020 3108 2002
Further details: After studying for an MSc in Midwifery in Iran I became a university lecturer; then after coming to the UK I obtained my second MSc in Prenatal Genetics and Fetal Medicine at the Institute for Women's Health in 2013. My thesis was in the cryopreservation of ovarian tissue to preserve fertility in women with cancer. The technique used was identifying viable follicles by Neutral Red staining to increase the chance of pregnancy after implantation of ovarian tissues with the highest follicle load. I joined Prof Widschwendter’s team in January 2014 on the EpiFemCare project and I am currently working on the FORECEE project. My responsibility is managing patient recruitment in UCLH and other collecting centres in London and the UK.
Ms Maria-Goretti Gonzales
Clinical Research Midwife
Further details: I studied my Nursing Degree at Universidad de Valladolid in Spain (2006) where I worked as an oncology nurse. I completed my BSc(Hons) in Midwifery at City University in 2011. Since then I have been working at University College London Hospital where I am currently a member of the research team working for The Baby Biome Study. In 2015 I obtained a Diploma in Tropical Nursing at the London School of Hygiene and Tropical Medicine.
In 2016 I joined the UCL Cancer Institute where I currently have the privilege of working within the recruitment team for the FORECEE project lead by Professor Martin Widschwendter. I have always had a huge interest in women's health research and female cancer prevention and therefore my goal is to study for a Master’s degree in Research in the near future.
Mr Richard Gunu
Research Associate/Biomedical Scientist
Dr Shaun Haran MBChB Hons
Specialist Clinical Trainee & Research Associate
Upon completion of my Bachelor of Medicine, Bachelor of Science (MBChB Hons) in 2010 I was awarded the academic prize in Obstetrics & Gynaecology. Having had a specialist interest in women’s cancers, over 2 years I worked at a Urological Specialist Cancer Unit as a surgical trainee and at the Royal Surrey County Hospital as a Clinical Fellow in Robotics & Gynaecological Oncology before entering specialty training in Obstetrics & Gynaecology in 2014. Having worked closely with the Gynaecological Oncology surgical team at University College London Hospital (UCLH) since 2015, I have recently been awarded a Clinical Academic Fellowship Award from UCLH that has allowed me the wonderful opportunity to work with Professor Martin Widschwendter and his academic team. I am currently actively collaborating with the BRCA PROTECT group and Professor Mark Lowdell, Director of the Centre for Cell, Gene & Tissue Therapy at the Royal Free Hospital London and University College London Cancer BioBank. Our aim is to better understand the immune function and its role in contributing to breast and ovarian cancer development in women with the BRCA mutation.
Ms Smita Karegodar
Tel: 020 3108 2008
Further details: I undertook my Bachelor of Computing degree in Applications from Gulbarga University, India in 2013. I joined Prof Widschwendter’s group in November 2014. I am actively involved in the BRCA PREVENT research project. My role is to maintain cell lines and to conduct molecular biology experiments for the BRCA PREVENT project. I am also responsible for updating the Department of Women’s Cancer website.
Dr Susanne Knapp
Tel: 020 3108 2002
Further details: I obtained my PhD in Molecular Genetics at the University of Cologne, Germany working in the field of Plant Genetics at the Max-Planck-Institute for Plant Breeding Research in Germany. Under a Capital and Mobility Fellowship from the EU I came to the UK to work on a biotechnology project at Unilever. After that I joined the Biotechnology team at Whitbread working on yeast and hops genetics. As I was fascinated by the challenges of working on human disease, I joined Imperial College London where I was involved in research projects around Genetic host factors associated with the susceptibility to HCV and HBV infection and HCC. From there my interest developed into the area of personalized medicine and I came to UCL in January 2016 to join Prof Martin Widschwendter’s group where we are working as a team on the development of a test to detect the risk of cancer in woman before the cancer arises. My main responsibility is to set up and run the Hamilton automation platform and process thousands of samples which we collect within Europe and prepare those samples for the analysis on the Illumina EPIC chip array.
Dr Dan Reisel
Senior Research Associate
Tel: 020 3108 2003
Further details: I have always been interested in how organisms change and adapt, and what happens when normal change is disrupted. For my PhD with Prof Nick Rawlins at the University of Oxford, I carried out physiological and behavioural characterisation of a transgenic mouse model with a conditional deletion of the AMPA1 glutamate receptor, showing that this receptor was key to temporary information storage in cells. After completing NHS Foundation Training in 2013, I started working in Prof Martin Widschwendter’s group, where I have helped to establish the FORECEE/4C Study, an international biosample study aimed at finding new ways to predict and prevent gynaecological and breast cancer. In 2016, I commenced a three-year NIHR-sponsored Academic Clinical Fellowship based at UCL, combining research into the epigenetics of women’s cancer with specialist training in Obstetrics & Gynaecology.
Dr Adam Rosenthal
Further details: I am a Consultant Gynaecologist and Lead Colposcopist at University College London Hospital. I have a longstanding interest in gynaecological cancer research focused on ovarian cancer screening and inherited gynaecological cancers. I am Clinical Lead on the UK Familial Ovarian Cancer Screening Study (UKFOCSS) and have published extensively in journals including the Lancet, Lancet Oncology, the Journal of Clinical Oncology and the British Journal of Cancer. I have been co-applicant on a number of grants from Cancer Research UK, NHS Research and Development, the Eve Appeal and the BUPA Foundation. My clinical interests are gynaecological cancers and precancers, colposcopy, laparoscopic and open surgery, anogenital neoplasia and inherited (familial) gynaecological cancers. I am currently actively collaborating in the BRCA PROTECT and FORECEE projects.
Dr Andy Ryan
Tel: 020 3447 2109
Further details: Degree from the Department of Zoology at Cambridge University. PhD in the molecular biology of the DNA repair syndrome xeroderma pigmentosum at the CRC Gray Laboratory. First postdoc position at the Biochemistry Department of Imperial College London identifying a X-linked zinc finger transcription factor gene. Moved to St. Barts, London to postdoc in the Gynaecological Cancer Research Group investigating the molecular genetics and epigenetics of ovarian cancer. In 2001 I took on the data management role for UKCTOCS, the world’s largest randomised controlled (ovarian) cancer screening trial, now in follow-up phase based at UCL. In 2013 I joined (part-time) the EpiFemCare project as data manager in the Translational Research Centre, UCL and I am currently involved in the FORECEE trial.
Mrs Sheila Spicer
BRCA PROTECT Clinic Administrator
Tel: 0020 3447 2125
Further details: I’m the Clinic Administrator for the BRCA PROTECT Research Clinic programme. I have been with the team for nearly two years, and have had the pleasure in seeing the programme grow from the early stages. I previously worked on the UKCTOCS trial, which I was part of for over 15 years, assisting the team with their clerical needs. It is a privilege to be part of a huge team at the Women’s Institute of Health and work alongside some great research projects that are always striving to enhance its knowledge of cancer and ways in which we can detect cancer early to help find a cure.
Dr Andrew Teschendorff
Newton Advanced Fellow & Principal Research Associate
Tel: 020 7679 0727
Further details: Andrew Teschendorff trained as a Theoretical Physicist at the University of Edinburgh and Cambridge University, where in May 2000 he obtained his PhD in Theoretical Particle Physics. He entered the field of Statistical Cancer Genomics in 2003, joining first the Breast Cancer Functional Genomics Lab at the University of Cambridge and later the UCL Cancer Institute at University College London. Currently, he is a Principal Investigator heading the Computational Systems Genomics at the CAS-MPG Partner Institute for Computational Biology in Shanghai. He also holds an appointment at the Department of Women’s Cancer UCL and a Newton Royal Society Fellowship at the UCL Cancer Institute. His broad research interest is in Statistical Cancer Epigenomics and Cancer System-omics. He has published over 100 papers in peer-reviewed journals, is Associate Editor for Epigenomics, BMC Systems Biology and Scientific Reports, and reviews regularly for many journals including Nature, JAMA, Nature Methods, Genome Research, Genome Biology, PLoS Computational Biology, and Bioinformatics. He is the recipient of various academic awards, including the Tait Medal and Robert Schlapp Prize in Physics (1995), the Jennings Prize (1996), a Cambridge-MIT Initiative Fellowship (2003-2005), an Isaac Newton Trust Award (2006), the Heller Research Fellowship (2008-2013), a Wellcome Trust VIP Award (2009-2010), and a CAS Visiting Professorship (2013-2014). He is the statistical lead on the Horizon 2020 FORECEE programme and holds 2 patents on Risk Prediction in Cancer
Ms Jiran Vatankhah Atashgah
Clinical Research Nurse
Further details: I am a Clinical Research Nurse working on the FORECEE, BRCA PROTECT and BRCA PREVENT projects. I joined Prof Widschwendter’s group in 2016. My role is to consent suitable patients and healthy volunteers for our research projects, collect blood, swabs, smear and tissue, and liaise with clinicians and research teams in order to obtain samples. Prior to joining UCL, I worked at UCLH for 12 years as a nurse and as a midwife.
Dr Nafisa Wilkinson MA MB BChir FRCPath
Gynae-Onc Consultant Pathologist at UCLH
Further Details: I am the lead Gynae-Onc Consultant Pathologist at UCLH. Apart from my role as pathologist, my research interests encompasses the pathophysiology of both Ovarian and Endometrial cancers. More specifically, I am interested in the mechanisms involved in the transition from hyperplasia to carcinoma in endometrioid endometrial carcinoma and the development of novel strategies for therapeutic intervention, in particular for younger women of reproductive age. From a clinical perspective, my interests lie with the identification of novel diagnostic markers for endometrial hyperplasia subtyping and prognostic markers of Ovarian carcinoma. With the latter I am interested in the pathogenesis of Ovarian cancer. My clinical areas of interest are also related to my research interests, i.e. Ovarian and endometrial cancers as well as mesenchymal tumours of the Uterus.
I am currently actively collaborating in the BRCA PROTECT and BRCA PREVENT projects and helping to establish BRCA mutant Fallopian Tube organoids and secretory epithelial cell lines to understand why BRCA mutation carriers develop serous tubal intraepithelial carcinoma (STIC) at the fimbrial end of the Fallopian Tube. Our aim is to devise preventive measures for populations at high risk of high-grade serous ovarian cancer.
- University College London, United Kingdom
- Karolinska Institutet, Sweden
- Charles University Hospital, Czech Republic
- Haukeland University Hospital, University of Bergen, Norway
- European Institute of Oncology, Italy
- Ludwig-Maximilians Universität, Munich, Germany
- London School of Hygiene and Tropical Medicine, United Kingdom
- Erasmus MC, The Netherlands
- Oncotyrol Center for Personalized Cancer Medicine, Austria
- Max Planck Institute for Human Development, Germany
- GATC Biotech, Germany
Funding, Support and Links
Following the European Research Council competitive call, the BRCA-ERC Study was successful and received 2.5M Euro from the European Research Council – ERC Advanced Grant 2016.
Horizon 2020: The EU Framework Programme for Research and Innovation. Following a very competitive call, the FORECEE Study was successful and received 8M Euro from the Horizon 2020 programme.
The Eve Appeal is a registered charity, formed in 2005. Since then, they have worked hard to raise money to fund the world-class research programme at the Department of Women's Cancer based at University College London (UCL).
The Department's vital and much-needed research will benefit women in the UK and worldwide.
The EpiFemCare project is being conducted by a pan-European consortium, which was formed in November 2012, and involves 5 European countries. The project is establishing and clinically validating a series of blood tests based upon biochemical changes detected in DNA released from ovarian and breast cancers.
Achieving the translational potential of the UCL UKCTOCS cohort and biobank in disease risk assessment, screening and prognostic prediction.
General Programme links
Widschwendter M, Jones A, Evans I, Reisel D, Dillner J, Sundström K, Steyerberg EW, Vergouwe Y, Wegwarth O, Rebitschek FG, Siebert U, Sroczynski G, de Beaufort ID, Bolt I, Cibula D, Zikan M, Bjørge L, Colombo N, Harbeck N, Dudbridge F, Tasse AM, Knoppers BM, Joly Y, Teschendorff AE, Pashayan N; FORECEE (4C) Consortium. Epigenome-based cancer risk prediction: rationale, opportunities and challenges. Nat Rev Clin Oncol. (2018 Feb 27); doi: 10.1038/nrclinonc.2018.30. [Epub ahead of print] Review. PMID: 29485132.
Lawn RB, Anderson EL, Suderman M, Simpkin AJ, Gaunt TR, Teschendorff AE, Widschwendter M, Hardy R, Kuh D, Relton CL, Howe LD. Psychosocial adversity and socioeconomic position during childhood and epigenetic age: analysis of two prospective cohort studies. Hum Mol Genet. (2018 Jan 22); doi: 10.1093/hmg/ddy036. [Epub ahead of print]. PMID: 29365106.
Widschwendter M, Evans I, Jones A, Ghazali S, Reisel D, Ryan A, Gentry-Maharaj A, Zikan M, Cibula D, Eichner J, Alunni-Fabbroni M, Koch J, Janni WJ, Paprotka T, Wittenberger T, Menon U, Wahl B, Rack B, Lempiäinen H. Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Med. (2017 Dec 22); 9(1):115. doi: 10.1186/s13073-017-0499-9. PMID: 29268762.
Widschwendter M, Zikan Z, Wahl B, Lempiäinen H, Paprotka T, Evans I, Jones A, Ghazali S, Reisel D, Eichner J, Rujan T, Yang Z, Teschendorff AE, Ryan A, Cibula D, Menon U, Wittenberger T. The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Med. (2017 Dec 22); 9(1):116. doi: 10.1186/s13073-017-0500-7. PMID: 29268796.
Chen Y, Vingron M, Widschwendter M, Teschendorff AE. Systems-epigenomics inference of transcription factor activity implicates arylhydrocarbon-receptor inactivation as a key event in lung cancer development. Genome Biol. (2017 Dec 20); 18(1):236 DOI 10.1186/s13059-017-1366-0. PMID: 29262847.
Ong JS, Hwang LD, Cuellar-Partida G, Martin NG, Chenevix-Trench G, Quinn MCJ, Cornelis MC, Gharahkhani P, Webb PM, MacGregor S; Ovarian Cancer Association Consortium (Bowtell D, deFazio A, Gertig D, Green A, Parsons P, Hayward N, Whiteman D, Peuteman G, Van Brussel T, Smeets D, Gacucova L, Schurmann P, Kramer F, Zheng W, Park TW, Simon, Beer-Grondke K, Schmidt D, Windebank S, Hilker C, Vollenweider J, Paddock L, King M, Rodriguez-Rodriguez L, Samoila A, Bensman Y, Sherman M, Hutchinson A, Szeszenia-Dabrowska N, Peplonska B, Zatonski W, Soni A, Chao P, Stagner M, Luccarini C, Harrington P, Jacobs I, Widschwendter M, Wozniak E, Balogun N, Ryan A, Karpinskyj C, Ford J, Pye C, Amin Al Olama A, Dennis J, Dicks E, Michilaidou K, Kuchenbaker K, Ong JS, Hwang LD, Cuellar-Partida G, Bryne E, Fasching PA, Hein A, Burghaus S, Beckmann MW, Lambrechts D, Van Nieuwenhuysen E, Vergote I, Vanderstichele A, Swerdlow AJ, Jones M, Orr N, Schoemaker M, Edwards DV, Brenton J, Benítez J, García MJ, Rodriguez-Antona C, Rossing MA, Fortner RT, Riboli E, Chang-Claude J, Eilber U, Wang-Gohrke S, Yannoukakos D, Goodman MT, Bogdanova N, Dörk T, Duerst M, Hillemanns P, Runnebaum IB, Antonenkova N, Butzow R, Nevanlinna H, Pelttari LM, Edwards RP, Kelley JL, Modugno F, Moysich KB, Ness RB, Cannioto R, Heitz F, Karlan B, Olsson H, Kjaer SK, Jensen A, Giles GG, Bruinsma F, Hildebrandt MAT, Liang D, Wu X, Le Marchand L, Setiawan VW, Permuth JB, Bisogna M, Dao F, Levine DA, Cramer DW, Terry KL, Tworoger SS, Stampfer M, Willet W, Missmer S, Bjorge L, Kopperud RK, Bischof K, Vestrheim Thomsen LC, Kiemeney LA, Massuger LF, Pejovic T, Brooks-Wilson A, Olson SH, McGuire V, Rothstein JH, Sieh W, Whittemore AS, Cook LS, Le ND, Gilks CB, Gronwald J, Jakubowska A, Lubiński J, Kluz T, Wentzensen N, Brinton L, Trabert B, Lissowska J, Høgdall E, Høgdall CK, Sandler DP, Wolk A, Tyrer JP, Song H, Eccles D, Campbell I, Glasspool R, McNeish I, Paul J, Siddiqui N, Sutphen R, McLaughlin JR, Phelan C, Anton-Culver H, Ziogas A, May T, Gayther SA, Gentry-Maharaj A, Menon U, Ramus SJ, Wu AH, Huntsman D, deFazio A, Dansonka-Mieszkowska A, Kupryjanczyk J, Moes-Sosnowska J, Szafron LM, Cunningham JM, Winham SJ, Risch HA, Goode EL, Schildkraut JM, Pearce CL, Berchuck A, Pharoah PDP, Martin NG, Chenevix-Trench G, Quinn MCJ, Cornelis MC, Gharahkhani P, Webb PM, MacGregor S). Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol. (2017 Nov 25); 1-10. doi: 10.1093/ije/dyx236. [Epub ahead of print]. PMID: 29186515.
Simpkin AJ, Cooper R, Howe LD, Relton CL, Davey Smith G, Teschendorff AE, Widschwendter M, Wong A, Kuh D, Hardy R. Are objective measures of physical capability related to accelerated epigenetic age? Findings from a British birth cohort. BMJ Open. (2017 Nov 1); 7(10):e016708. doi: 10.1136/bmjopen-2017-016708. PMID: 29092899.
Ovarian Tumor Tissue Analysis (OTTA) Consortium, Goode EL, Block MS, Kalli KR, Vierkant RA, Chen W, Fogarty ZC, Gentry-Maharaj A, Toloczko A, Hein A, Bouligny AL, Jensen A, Osorio A, Hartkopf AD, Ryan A, Chudecka-Glaz A, Magliocco AM, Hartmann A, Jung AY, Gao B, Hernandez BY, Fridley BL, McCauley BM, Kennedy CJ, Wang C, Karpinskyj C, de Sousa CB, Tiezzi DG, Wachter DL, Herpel E, Taran FA, Modugno F, Nelson G, Lubinski J, Menkiszak J, Alsop J, Lester J, García-Donas J, Nation J, Hung J, Palacios J, Rothstein JH, Kelley JL, de Andrade JM, Robles-Díaz L, Intermaggio MP, Widschwendter M, Beckmann MW, Ruebner M, Jimenez-Linan M, Singh N, Oszurek O, Harnett PR, Rambau PF, Sinn P, Wagner P, Ghatage P, Sharma R, Edwards RP, Ness RB, Orsulic S, Brucker SY, Johnatty SE, Longacre TA, Eilber U, McGuire V, Sieh W, Natanzon Y, Li Z, Whittemore AS, deFazio A, Staebler A, Karlan BY, Gilks B, Bowtell DD, Høgdall E, Candido Dos Reis FJ, Steed H, Campbell IG, Gronwald J, Benítez J, Koziak JM, Chang-Claude J, Moysich KB, Kelemen LE, Cook LS, Goodman MT, García MJ, Fasching PA, Kommoss S, Deen S, Kjaer SK, Menon U, Brenton JD, Pharoah PDP, Chenevix-Trench G, Huntsman DG, Winham SJ, Köbel M, Ramus SJ. Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncol. (2017 Oct 12); e173290. doi: 10.1001/jamaoncol.2017.3290. [Epub ahead of print]. PMID: 29049607.
Nunes N, Ambler G, Foo X, Widschwendter M, Jurkovic D. A prospective evaluation of the IOTA Logistic Regression Models (LR1 and LR2) in comparison to Subjective Pattern Recognition for the diagnosis of ovarian cancer in the outpatient setting. Ultrasound Obstet Gynecol. (2017 Oct 4); doi: 10.1002/uog.18918. [Epub ahead of print]. PMID: 28976616
Tomar T, Alkema NG, Schreuder L, Meersma GJ, de Meyer T, van Criekinge W, Klip HG, Fiegl H, van Nieuwenhuysen E, Vergote I, Widschwendter M, Schuuring E, van der Zee AGJ, de Jong S, Wisman GBA. Methylome analysis of extreme chemoresponsive patients identifies novel markers of platinum sensitivity in high-grade serous ovarian cancer. BMC Med. (2017 Jun 23); 15(1):116. doi: 10.1186/s12916-017-0870-0.
Nunes N, Ambler G, Foo X, Naftalin J, Derdelis G, Widschwendter M, Jurkovic D. Comparison of two protocols for the management of asymptomatic postmenopausal women with adnexal tumours - a randomised controlled trial of RMI/RCOG vs Simple Rules. Br J Cancer. (2017 Feb 28); 116(5):584-591. doi: 10.1038/bjc.2017.17. Epub 2017 Feb 2.
Wong M, Crnobrnja B, Liberale V, Dharmarajah K, Widschwendter M, Jurkovic D. The natural history of endometrial polyps. Hum. Reprod. (2017 Feb); 32(2):340-345. doi: 10.1093/humrep/dew307.
Kazarian A, Blyuss O, Metodieva G, Gentry-Maharaj A, Ryan A, Kiseleva EM, Prytomanova OM, Jacobs IJ, Widschwendter M, Menon U, Timms JF. Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. Br J Cancer. (2017 Feb 14); 116(4):501-508. doi: 10.1038/bjc.2016.433.
Milani A, Kristeleit R, McCormack M, Raja F, Luvero D, Widschwendter M, MacDonald N, Mould T, Olatain A, Hackshaw A, Ledermann JA. Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy. ESMO Open. (2017 Jan 31);1(6):e000117. doi: 10.1136/esmoopen-2016-000117. eCollection 2016. PMID:28848659.
Marchetti C, Kristeleit R, McCormack M, Mould T, Olaitan A, Widschwendter M, MacDonald N, Ledermann JA. Outcome of patients with advanced ovarian cancer who do not undergo debulking surgery: A single institution retrospective review. Gynecol Oncol. (2017 Jan); 144(1):57-60. doi: 10.1016/j.ygyno.2016.11.001.
Kiechl S, Schramek D, Widschwendter M, Fourkala EO, Zaikin A, Jones A, Jaeger B, Rack B, Janni W, Scholz C, Willeit J, Weger S, Mayr A, Teschendorff A, Rosenthal A, Fraser L, Philpott S, Dubeau L, Keshtgar M, Roylance R, Jacobs IJ, Menon U, Schett G, Penninger JM. Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget. (2017 Jan 17); 8(3):3811-3825. doi: 10.18632/oncotarget.14013.
Yang Z, Wong A, Kuh D, Paul D, Rakyan VK, Leslie RD, Zheng SC, Widschwendter M, Beck S, Teschendorff AE. Correlation of an epigenetic mitotic clock with cancer risk. Genome Biol. (2016 Oct 3); 17(1):205.
Kalwa M, Haenzelmann S, Otto S, Kuo C-C, Franzen J, Joussen S, Fernandez Rebollo E, Rath B, Koch C, Hofmann A, Lee S-H, Teschendorff A, Denecke B, Lin Q, Widschwendter M, Weinhold E, Costa I, Wagner W. The lncRNA HOTAIR Impacts on Mesenchymal Stem Cells via Triple Helix Formation. Nucl Acid Res. (2016 Sep 15); 44(22):10631-10643.
Teschendorff AE, Zheng SC, Feber A, Yang Z, Beck S, Widschwendter M. The multi-omic landscape of transcription factor inactivation in cancer. Genome Med. (2016 Aug 25); 8(1):89. doi: 10.1186/s13073-016-0342-8.
Levine ME, Lu AT, Chen BH, Hernandez DG, Singleton AB, Ferrucci L, Bandinelli S, Salfati E, Manson JE, Quach A, Kusters CDJ, Kuh D, Wong A, Teschendorff AE, Widschwendter M, Ritz BR, Absher D, Assimes T, Horvath S. Menopause Accelerates Biological Aging. Proc Natl Acad Sci USA. (2016 Aug 16); 113(33):9327-32. doi: 10.1073/pnas.1604558113. Epub 2016 Jul 25.
Lemech CR, Ensell L, Paterson JC, Eminowicz G, Lowe H, Arora R, Arkenau HT, Widschwendter M, MacDonald N, Olaitan A, Mould T, Meyer T, Hartley J, Mitra A, Ledermann JA, McCormack M, Kristeleit RS. Enumeration and Molecular Characterisation of Circulating Tumour Cells in Endometrial Cancer. Oncology. (2016 Jun 3); 91(1):48-54.
Doufekas K, Zheng SC, Ghazali S, Wong M, Mohamed Y, Jones A, Reisel D, Mould T, Olaitan A, Macdonald N, Teschendorff A, Widschwendter M. DNA methylation signatures in vaginal fluid samples for detection of cervical and endometrial cancer. Int J Gynecol Cancer. (2016 Jun 2). [Epub ahead of print].
Gao Y, Jones A, Fasching P, Ruebner M, Beckmann MW, Widschwendter M and Teschendorff A. The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. Clin Epigenetics. (2016 Jun 1); 8:63. eCollection 2016.
Bartlett TE, Chindera K, McDermott J, Breeze C, Cooke WR, Jones A, Reisel D, Karegodar ST, Arora R, Beck S, Menon U, Dubeau L, Widschwendter M. Epigenetic reprogramming of Fallopian tube fimbriae in BRCA mutation carriers defines ovarian cancer evolution. Nature Communications. (2016 May 24); 7:11620. doi: 10.1038/ncomms11620.
Lim A, Mesher D, Gentry-Maharaj A, Balogun N, Widschwendter M, Jacobs I, Sasieni P, Menon U. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. BJOG. (2016 May); 123(6):1012-20. doi: 10.1111/1471-0528.13447. Epub 2015 May 29.
Zheng SC, Widschwendter M, Teschendorff AE. Epigenetic drift, epigenetic clocks and cancer risk. Epigenomics. (2016 May); 8(5):705-19. doi: 10.2217/epi-2015-0017.
Teschendorff AE, Jones A, Widschwendter M. Stochastic epigenetic outliers can define field defects in cancer. BMC Bioinformatics. (2016 Apr 22); 17:178. doi: 10.1186/s12859-016-1056-z.
Jacobs IJ, Menon U, Ryan A, Gentry-Maharaj A, Burnell M, Kalsi JK, Amso NN, Apostolidou S, Benjamin E, Cruickshank D, Crump DN, Davies SK, Dawnay A, Dobbs S, Fletcher G, Ford J, Godfrey K, Gunu R, Habib M, Hallett R, Herod J, Jenkins H, Karpinskyj C, Leeson S, Lewis SJ, Liston WR, Lopes A, Mould T, Murdoch J, Oram D, Rabideau DJ, Reynolds K, Scott I, Seif MW, Sharma A, Singh N, Taylor J, Warburton F, Widschwendter M, Williamson K, Woolas R, Fallowfield L, McGuire AJ, Campbell S, Parmar M, Skates SJ. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. The Lancet. (2016 Mar 5); 387(10022):945-56. doi: 10.1016/S0140-6736(15)01224-6. Epub 2015 Dec 17. Erratum in: Lancet. 2016 Mar 5;387(10022):944.
Pashayan N, Reisel D, Widschwendter M. Integration of genetic and epigenetic markers for risk stratification: opportunities and challenges. Pers Med. (2016 Mar 1); 13(2):93-95.
Teschendorff AE Gao Y, Jones A, Ruebner M, Beckmann MW, Wachter DL, Fasching PA, Widschwendter M. DNA methylation outliers in normal breast tissue identify field defects that are enriched in cancer. Nature Communications. (2016 Jan 29); 7:10478. doi: 10.1038/ncomms10478.
Pharoah PDP, Song H, Dicks E, Intermaggio MP, Harrington P, Baynes C, Alsop K, AOCS Study Group Bogdanova N, Cicek MS, Cunningham JM, Fridley BL, Gentry-Maharaj A, Hillemanns P, Lele S, Lester J, McGuire V, Moysich KB, Poblete S, Sieh W, Sucheston-Campbell L, Widschwendter M, Ovarian Cancer Association Consortium, Whittemore AS, Dörk T, Menon U, Odunsi K, Goode EL, Karlan BY, Bowtell DD, Gayther SA, Ramus SJ. PPM1D mosaic truncating variants in ovarian cancer cases may be treatment related somatic mutations. Journal of the National Cancer Institute. (2016 Jan 27); 108(3). pii: djv347. doi: 10.1093/jnci/djv347. Print 2016 Mar.
Paul DS, Jones A, Sellar RS, Mayor NP, Feber A, Webster AP, Afonso N, Sergeant R, Szydlo RM, Apperley JF, Widschwendter M, Mackinnon S, Marsh SGE, Madrigal JA, Rakyan VK, Peggs KS, Beck S. A donor-specific epigenetic classifier for acute graft-versus-host disease severity in hematopoietic stem cell transplantation. Genome Med. (2015 Dec) 7:128. DOI 10.1186/s13073-015-0246-z.
Gao Y, Jones A, Fasching P, Ruebner M, Beckmann MW, Widschwendter M and Teschendorff A. The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. Clinical Epigenetics. (2015 Dec 9); 7: 126. DOI 10.1186/s13148-015-0159-0.
Bartlett TE, Jones A, Goode EL, Fridley BL, Cunningham JM, Berns EMJJ, Wik E, Salvesen HB, Davidson B, Trope CG, Lambrechts S, Vergote I, Widschwendter M. Intra-Gene DNA Methylation Variability is a Clinically Independent Prognostic Marker in Women's Cancers. PLoS One. (2015 Dec 2); 10(12):e0143178. doi: 10.1371/journal.pone.0143178.
Teschendorff AE, Lee SH, Jones A, Fiegl H, Kalwa M, Wagner W, Chindera K, Evans I, Dubeau L, Orjalo A, Horlings HM, Niederreiter L, Kaser A, Yang W, Goode EL, Fridley BL, Jenner RG, Berns EM, Wik E, Salvesen HB, Wisman GB, van der Zee AG, Davidson B, Trope CG, Lambrechts S, Vergote I, Calvert H, Jacobs IJ, Widschwendter M. HOTAIR And Its Surrogate DNA Methylation Signature Indicate Carboplatin Resistance In Ovarian Cancer. Genome Med. (2015 Oct 24); 7(1):108. doi: 10.1186/s13073-015-0233-4.
Liu Y, Pike MC, Wu N, Lin YG, Mucowski S, Punj V, Tang Y, Yen HY, Stanczyk FZ, Enbom E, Austria T, Widschwendter M, Maxson R, Dubeau L. Brca1 Mutations Enhance Mouse Reproductive Functions by Increasing Responsiveness to Male-Derived Scent. PLoS One. (2015 Oct 21); 10(10):e0139013. doi: 10.1371/journal.pone.0139013.
Liu Y, Yen HY, Austria T, Pettersson J, Peti-Peterdi J, Maxson R, Widschwendter M, Dubeau L. A Mouse Model That Reproduces the Developmental Pathways and Site Specificity of the Cancers Associated With the Human BRCA1 Mutation Carrier State.mutation carrier state. EBioMedicine. (2015 Sep 09); 2(10): 1318–1330. doi.org/10.1016/j.ebiom.2015.08.034.
Widschwendter M, Burnell M, Fraser S, Rosenthal AN, Philpott S, Reisel D, Dubeau L, Cline M, Pan Y, Ping-Cheng Y, Evans DG, Jacobs IJ, Menon U, Wood CE, Dougall WC. Osteoprotegerin (OPG), the Endogenous Inhibitor of Receptor Activator of NF-κB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine. (2015 Sep 09); 2(10): 1331–1339. doi.org/10.1016/j.ebiom.2015.08.037.
Yang Z, Jones A, Widschwendter M, Teschendorff AE. An integrative pan-cancer-wide analysis of epigenetic enzymes reveals universal patterns of epigenomic deregulation in cancer. Genome Biol. (2015 Jul 14); 16(1):140. doi: 10.1186/s13059-015-0699-9.
Teschendorff AE, Yang Z, Wong A, Pipinikas CP, Jiao Y, Jones A, Anjum S, Hardy R, Salvesen HB, Thirlwell C, Janes SM, Kuh D, Widschwendter M. Correlation of Smoking-Associated DNA Methylation Changes in Buccal Cells With DNA Methylation Changes in Epithelial Cancer. JAMA Oncol. (2015 Jul 1); 1(4):476-85. doi: 10.1001/jamaoncol.2015.1053.
Lim A, Mesher D, Gentry-Maharaj A, Balogun N, Widschwendter M, Jacobs I, Sasieni P, Menon U. Time to diagnosis of Type I or II invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. BJOG. (2015 May 29); doi: 10.1111/1471-0528.13447. [Epub ahead of print].
Menon U, Ryan A, Kalsi J, Gentry-Maharaj A, Dawnay A, Habib M, Apostolidou S, Singh N, Benjamin E, Burnell M, Davies S, Sharma A, Gunu R, Godfrey K, Lopes A, Oram D, Herod J, Williamson K, Seif MW, Jenkins H, Mould T, Woolas R, Murdoch JB, Dobbs S, Amso NN, Leeson S, Cruickshank D, Scott I, Fallowfield L, Widschwendter M, Reynolds K, McGuire A, Campbell S, Parmar M, Skates SJ, Jacobs I. Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. J Clin Oncol. (2015 Jun 20); 33(18):2062-71. doi: 10.1200/JCO.2014.59.4945. Epub 2015 May 11.
Köbel M, Madore J, Ramus SJ, Clarke BA, Pharoah PD, Deen S, Bowtell DD, Odunsi K, Menon U, Morrison C, Lele S, Bshara W, Sucheston L, Beckmann MW, Hein A, Thiel FC, Hartmann A, Wachter DL, Anglesio MS, Høgdall E, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Fogarty ZC, Vierkant RA, Liu S, Cho S, Nelson G, Ghatage P, Gentry-Maharaj A, Gayther SA, Benjamin E, Widschwendter M, Intermaggio MP, Rosen B, Bernardini MQ, Mackay H, Oza A, Shaw P, Jimenez-Linan M, Driver KE, Alsop J, Mack M, Koziak JM, Steed H, Ewanowich C, DeFazio A, Chenevix-Trench G, Fereday S, Gao B, Johnatty SE, George J, Galletta L; AOCS Study Group, Goode EL, Kjær SK, Huntsman DG, Fasching PA, Moysich KB, Brenton JD, Kelemen LE. Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. Br J Cancer. (2014 Dec 9); 111(12):2297-2307. doi: 10.1038/bjc.2014.567. Epub 2014 Oct 30.
Loddo M, Andryszkiewicz J, Rodriguez-Acebes S, Stoeber K, Jones A, Dafou D, Apostolidou S, Wollenschlaeger A, Widschwendter M, Sainsbury R, Tudzarova S, Williams GH. Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer. J Pathol. (2014 Aug); 233(4):344-56. doi: 10.1002/path.4393.
Jiao Y, Widschwendter M, Teschendorff AE. A systems-level integrative framework for genome-wide DNA methylation and gene expression data identifies functional gene modules under epigenetic control. Bioinformatics (2014 Aug 15); 30(16):2360-6. doi: 10.1093/bioinformatics/btu316. Epub 2014 May 2.
Teschendorff AE, Liu X, Caren H, Pollard SM, Beck S, Widschwendter M, Chen L. The Dynamics of DNA Methylation Covariation Patterns in Carcinogenesis. PLoS Comput Biol. (2014 Jul 10); 10(7): e1003709. doi: 10.1371/journal.pcbi.1003709. eCollection 2014.
Anjum S, Fourkala E-O, Zikan M, Wong A, Gentry-Maharaj A, Jones A, Hardy R, Cibula D, Kuh D, Jacobs IJ, Teschendorff AE, Menon U, Widschwendter M. A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Med. (2014 Jun 27); 6(6):47. doi: 10.1186/gm567. eCollection 2014.
Almouzni G, Altucci L, Amati B, Ashley N, Baulcombe D, Beaujean N, Bock C, Bongcam-Rudloff E, Bousquet J, Braun S, Paillerets BB, Bussemakers M, Clarke L, Conesa A, Estivill X, Fazeli A, Grgurević N, Gut I, Heijmans BT, Hermouet S, Houwing-Duistermaat J, Iacobucci I, Ilaš J, Kandimalla R, Krauss-Etschmann S, Lasko P, Lehmann S, Lindroth A, Majdič G, Marcotte E, Martinelli G, Martinet N, Meyer E, Miceli C, Mills K, Moreno-Villanueva M, Morvan G, Nickel D, Niesler B, Nowacki M, Nowak J, Ossowski S, Pelizzola M, Pochet R, Potočnik U, Radwanska M, Raes J, Rattray M, Robinson MD, Roelen B, Sauer S, Schinzer D, Slagboom E, Spector T, Stunnenberg HG, Tiligada E, Torres-Padilla ME, Tsonaka R, Soom AV, Vidaković M, Widschwendter M. Relationship between genome and epigenome - challenges and requirements for future research. BMC Genomics (2014 Jun 18); 15:487. doi:10.1186/1471-2164-15-487.
Nunes N, Ambler G, Foo X, Naftalin J, Widschwendter M, Jurkovic D. Use of the IOTA Simple Rules for the diagnosis of ovarian cancer: a Meta-Analysis. Ultrasound Obstet Gynecol. (2014 Jun 11). doi: 10.1002/uog.13437. [Epub ahead of print].
Wittenberger T, Sleigh S, Reisel D, Zikan M, Wahl B, Alunni-Fabbroni M, Jones A, Evans I, Koch J, Paprotka T, Lempiäinen H, Rujan T, Rack B, Cibula D, Widschwendter M. DNA methylation markers for early detection of women’s cancer – promise and challenges. Epigenomics (2014 Jun); 6(3):311-327.
Del Rincón SV*, Widschwendter M*, Sun D, Ekholm-Reed S, Tat J, Teixeira LK, Ellederova Z, Grolieres E, Reed SI, Spruck C. Cks Overexpression Enhances Chemotherapeutic Efficacy by Overriding DNA Damage Checkpoints. Oncogene (2014 May 26). doi: 10.1038/onc.2014.137. [Epub ahead of print]. *equally contributed.
Tan Y, Sun D, Jiang W, Klotz-Noack K, Vashisht AV, Wohlschlegel J, Widschwendter M, Spruck C. PP2A-B55β Antagonizes Cyclin E1 Proteolysis and Promotes its Dysregulation in Cancer. Cancer Res. (2014 Apr 1); 74(7):2006-14. doi: 10.1158/0008-5472.CAN-13-1263. Epub 2014 Feb 7.
Hoivik EA, Kusonmano K, Halle MK, Berg A, Wik E, Werner HM, Petersen K, Oyan AM, Kalland KH, Krakstad C, Trovik J, Widschwendter M, Salvesen HB. Hypomethylation of the CTCFL/BORIS promoter and aberrant expression during endometrial cancer progression suggests a role as an Epi-driver gene. Oncotarget (2014 Feb 28); 5(4):1052-61.
Jones A, Teschendorff AE, Li Q, Hayward JD, Kannan A, Mould T, West J, Zikan M, Cibula D, Fiegl H, Lee S-H, Wik E, Hadwin R, Arora R, Lemech C, Turunen H, Pakarinen P, Jacobs IJ, Salvesen HB, Bagchi MK, Bagchi IC, Widschwendter M. Role of DNA Methylation and Epigenetic Silencing of HAND2 in Endometrial Cancer Development. PLoS MED. (2013 Nov 12); 10(11): e1001551.
Banerji CR, Miranda-Saavedra D, Severini S, Widschwendter M, Enver T, Zhou JX, Teschendorff AE. Cellular network entropy as the energy potential in Waddington’s differentiation landscape. Scientific Reports (2013 Oct 24); 3:3039. doi: 10.1038/srep03039.
Widschwendter M, Rosenthal AN, Philpott S, Rizzuto I, Fraser L, Hayward J, Intermaggio MP, Edlund CK, Ramus SJ, Gayther SA, Dubeau L, Fourkala EO, Zaikin A, Menon U, and Jacobs IJ. The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. The Lancet Oncology (2013 Nov); 14(12): 1226–32. Published Online October 17, 2013. http://dx.doi.org/10.1016/ S1470-2045(13)70448-0.
Nunes N, Ambler G, Hoo WL, Naftalin J, Foo X, Widschwendter M, Jurkovic D. A Prospective Validation of the IOTA Logistic Regression Models (LR1 and LR2) in Comparison to Subjective Pattern Recognition for the Diagnosis of Ovarian Cancer. Int J Gynecol Cancer (2013 Nov); 23(9):1583-9. doi: 10.1097/IGC.0b013e3182a6171a.
West J, Widschwendter M, Teschendorff AE. Distinctive topology of age-associated epigenetic drift in the human interactome. Proc Natl Acad Sci USA (2013 Aug 27); 110(35):14138-43. doi: 10.1073/pnas.1307242110. Epub 2013 Aug 12.
Bartlett TE, Zaikin A, Olhede SC, West J, Teschendorff AE, Widschwendter M. Corruption of the intra-gene DNA methylation architecture is a hallmark of cancer. PLoS One (2013 Jul 16); 8(7):e68285. doi: 10.1371/journal.pone.0068285. Print 2013.
Cepeda D, Ng HF, Sharifi HR, Mahmoudi S, Cerrato VS, Fredlund E, Magnusson K, Nilsson H, Malyukova A, Rantala J, Klevebring D, Viñals F, Bhaskaran N, Zakaria SM, Rahmanto AS, Grotegut S, Nielsen ML, Szigyarto CA, Sun D, Lerner M, Navani S, Widschwendter M, Uhlén M, Jirström K, Pontén F, Wohlschlegel J, Grandér D, Spruck C, Larsson LG, Sangfelt O. CDK-mediated activation of the SCF(FBXO) (28) ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer. EMBO Mol Med. (2013 Jul); 5(7):999-1018. doi: 10.1002/emmm.201202341. Epub 2013 Jun 14.
Doufekas K, Hadwin R, Kandimalla R, Jones A, Mould T, Crowe S, Olaitan A, Macdonald N, Fiegl H, Wik E, Salvesen HB, Widschwendter M. GALR1 Methylation in Vaginal Swabs Is Highly Accurate in Identifying Women With Endometrial Cancer. Int J Gynecol Cancer (2013 Jul); 23(6): 1050-5. doi: 10.1097/IGC.0b013e3182959103.
Widschwendter M, Jones A, Teschendorff AE. Epigenetics makes its mark on women-specific cancers--an opportunity to redefine oncological approaches? Gynecol Oncol. (2013 Jan); 128(1):134-43. doi: 10.1016/j.ygyno.2012.09.027. Epub 2012 Oct 1.
Nunes N, Foo X, Widschwendter M, Jurkovic D. A randomised controlled trial comparing surgical intervention rates between two protocols for the management of asymptomatic adnexal tumours in postmenopausal women. BMJ Open (2012 Dec 11); 2(6). doi:pii: e002248. 10.1136/bmjopen-2012-002248. Print 2012.
Balogun N, Forbes A, Widschwendter M, Lanceley A. Noninvasive nutritional management of ovarian cancer patients: beyond intestinal obstruction. Int J Gynecol Cancer (2012 Jul); 22(6):1089-95. doi: 10.1097/IGC.0b013e318256e4d3.
Teschendorff AE and Widschwendter M. Differential variability improves the identification of cancer risk markers in DNA methylation studies profiling precursor cancer lesions. Bioinformatics (2012 Jun 1); 28(11):1487-94. doi: 10.1093/bioinformatics/bts170. Epub 2012 Apr 6.
Fourkala EO, Gentry-Maharaj A, Burnell M, Ryan, A, Manchanda R, Dawnay A, Jacobs I, Widschwendter M, Menon U. Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. British Journal of Cancer (2012 Jun 5); 106(12):1910-6. doi: 10.1038/bjc.2012.155. Epub 2012 May 17.
Zhuang J, Widschwendter M, Teschendorff AE. A comparison of feature selection and classification methods in DNA methylation studies using the Illumina Infinium platform. BMC Bioinformatics (2012 Apr 24); 13:59. doi: 10.1186/1471-2105-13-59.
Fourkala EO, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, Soromani C, Hasenbrink G, Jacobs I, Dawnay A, Widschwendter M, Lichtenberg-Fraté H, Menon U. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocr Relat Cancer (2012 Apr 10); 19(2):137-47. doi: 10.1530/ERC-11-0310. Print 2012 Apr.
Teschendorff AE, Jones A, Fiegl H, Sargent A, Zhuang J, Kitchener H & Widschwendter M. Epigenetic variability in cells of normal cytology is associated with the risk of future morphological transformation. Genome Medicine (2012 Mar 27); 4(3):24.
Zhuang J, Jones A, Lee SH, Ng E, Fiegl H, Zikan M, Cibula D, Sargent A, Salvesen HB, Jacobs IJ, Kitchener HC, Teschendorff AE, Widschwendter M. The Dynamics and Prognostic Potential of DNA Methylation Changes at Stem Cell Gene Loci in Women’s Cancer. PLoS Genet. (2012 Feb); 8(2):e1002517. doi: 10.1371/journal.pgen.1002517. Epub 2012 Feb 9.
Rosenthal AN, Heron G, Widschwendter M, Read S, Brunell C, Mould TA. Fooled by the film: delayed diagnosis of incarcerated small-bowel hernia after laparoscopic surgery for endometrial cancer. Int J Gynecol Cancer (2012 Feb); 22(2):337-9. doi: 10.1097/IGC.0b013e31823c244b.
Liberal V, Martinsson-Ahlzén H, Liberal J, Spruck C, Widschwendter M, McGowan C, and Reed SI. Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins. Proc Natl Acad Sci USA (2012 Feb 21); 109(8):2754-9. doi: 10.1073/pnas.1102434108. Epub 2011 Jun 22.
Goebel G, Berger R, Strasak M, Egle D, Mueller-Holzner E, Schmidt S, Rainer J, Presul E, Lang S, Jones A, Widschwendter M and Fiegl H. Elevated mRNA expression of CHAC1 splicing variants is associated with poor outcome for breast and ovarian cancer patients. Brit J Cancer (2012 Jan 3); 106(1):189-98.
Campan M, Moffitt M, Houshdaran S, Shen H, Widschwendter M, Daxenbichler G, Long T, Marth C, Laird-Offringa IA, Press MF, Dubeau L, Siegmund KD, Wu AH, Groshen S, Chandavarkar U, Roman LD, Berchuck A, Pearce CL, Laird PW. Genome-Scale Screen for DNA Methylation-Based Detection Markers for Ovarian Cancer. PLoS One (2011); 6(12):e28141. [
Koukoura O, Sifakis S, Soufla G, Zaravinos A, Apostolidou S, Jones A, Widschwendter M, Spandidos DA. Loss of imprinting and aberrant methylation of IGF2 in placentas from pregnancies complicated with fetal growth restriction. Int J Mol Med. (2011); 28(4):481-7.
Teschendorff AE, Zhuang J, Widschwendter M. Independent Surrogate Variable Analysis as a tool to deconvolve confounding factors in large-scale microarray profiling studies. Bioinformatics (2011 Jun 1); 27(11):1496-505.
Cibula D, Widschwendter M, Zikan M, Dusek L. Underlying mechanisms of ovarian cancer risk reduction after tubal ligation. Acta Obstet Gynecol Scand. (2011); 90(6):559-63. [IF: 1.850]
Cibula D, Widschwendter M, Dušek L. Tubal Ligation and the Risk of Ovarian Cancer – review and meta-analysis. Hum Reprod Update (2011); 17(1): 55-67.
Koukoura O, Sifakis S, Zaravinos A, Apostolidou S, Jones A, Hajiioannou J, Widschwendter M, Spandidos DA. Hypomethylation along with increased H19 expression in placentas from pregnancies complicated with fetal growth restriction. Placenta (2011); 32(1):51-7.
Akhoondi S, Lindstrom L, Widschwendter M, Corcoran M, Bergh J, Spruck C, Grander D, Sangfelt O. Inactivation of FBXW7/hCDC4-beta expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer. Breast Cancer Res. (2010); 12(6):R105.
Balogun N, Gentry-Maharaj A, Wozniak EL, Lim A, Ryan A, Ramus SJ, Ford J, Burnell M, Widschwendter M, Gessler SF, Gayther SA, Jacobs IJ, Menon U. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. J Clin Epidemiol. (2010); 64(5):525-30.
Schramek D, Leibbrandt A, Sigl V, Kenner L, Hanada R, Joshi P, Pospisilik JA, Lee H, Aliprantis A, Ormandy C, Glimcher L, Pasparakis M, Khoka R, Widschwendter M, Schett G, and Penninger JM. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature (2010 Nov 4); 468(7320): 98-102.
Goode E, Chenevix-Trench G, Song H, Ramus S , Notaridou M , Lawrenson K, Widschwendter M, et al., Ovarian Cancer Association Consortium. A Genome-Wide Association Study Identifies Susceptibility Loci for Ovarian Cancer at 2q31 and 8q24. Nat Genet. (2010 October); 42(10): 874–879.
del Rincón S, Rogers J, Widschwendter M, Sun D, Sieburg HB, and Spruck C. Development and Validation of a Method for Profiling Post-Translational Modification Activities Using Protein Microarrays. PLoS One (2010 Jun 28); 5(6):e11332. doi: 10.1371/journal.pone.0011332.
Berger R, Fiegl H, Goebel G, Obexer P, Ausserlechner M, Doppler W, Hauser-Kronberger C, Reitsamer R, Egle D, Reimer D, Muller-Holzner E, Jones A & Widschwendter M. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. (2010); 101: 1059-1066.
Thirlwell C, Eymard M, Feber A, Teschendorff A, Pearce K, Lechner M, Widschwendter M, Beck S. Genome-wide DNA methylation analysis of archival formalin-fixed paraffin-embedded tissue using the Illumina Infinium Human Methylation27 BeadChip. Methods (2010); 52(3): 248-254. [IF: 3.641]
Fourkala EO, Hauser-Kronberger C, Apostolidou S, Burnell M, Jones A, Grall J, Reitsamer R, Fiegl H, Jacobs I, Menon U & Widschwendter M. DNA methylation of polycomb group target genes in cores taken from breast cancer centre and periphery. Breast Cancer Res Treat. (2010); 120: 345-355.
Teschendorff AE, Menon U, Gentry-Maharaj A, Ramus SJ, Weisenberger DJ, Shen H, Campan M, Noushmehr H, Bell CG, Maxwell AP, Savage DA, Mueller-Holzner E, Marth C, Kocjan G, Gayther SA, Jones A, Beck S, Wagner W, Laird PW, Jacobs IJ & Widschwendter M. Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Res. (2010 Apr); 20(4): 440-446.
Jones A, Lechner M, Fourkala EO, Kristeleit R, Widschwendter M. Emerging promise of epigenetics and DNA methylation for the diagnosis and management of women's cancers. Epigenomics (2010 Feb); 2(1):9-38. doi: 10.2217/epi.09.47.
Widschwendter M, Apostolidou S, Jones AA, Fourkala EO, Arora R, Pearce CL, Frasco MA, Ayhan A, Zikan M, Cibula D, Iyibozkurt CA, Yavuz E, Hauser-Kronberger C, Dubeau L, Menon U & Jacobs IJ. HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: a proof of principle study. Int J Cancer (2009); 125: 2214-2218.
Teschendorff AE. Menon U, Gentry-Maharaj A, Ramus SJ, Gayther SA, Apostolidou S, Jones A, Lechner M, Beck S, Jacobs IJ & Widschwendter M. An epigenetic signature in peripheral blood predicts active ovarian cancer. PLoS One. (2009 dec); 4(12), e8274.
S. Apostolidou, R. Hadwin, M. Burnell, A. Jones, D. Baff, N. Pyndiah, T. Mould, I.J. Jacobs, S. Beddows, G. Kocjan, M. Widschwendter. DNA methylation analysis in liquid-based cytology for cervical cancer screening. Int J Cancer. (2009); 125:2995-3002.
M. Widschwendter, H. Lichtenberg-Frate, G. Hasenbrink, S. Schwarzer, A. Dawnay, A. Lam, U Menon, S. Apostolidou, E. Raum, C. Stegmaier, I.J. Jacobs, H. Brenner. Serum oestrogen receptor alpha and beta bioactivity are independently associated with breast cancer: a proof of principle study. Br J Cancer. (2009); 101:160-5.
M.Widschwendter, S.Apostolidou, E.Raum, D.Rothenbacher, H.Fiegl, U.Menon, C.Stegmaier, I.J.Jacobs, H.Brenner. Epigenotyping in peripheral blood cell DNA and breast cancer risk: a proof of principle study. PLoS One (2008 Jul 16); 3(7):e2656.
H.Fiegl, A.Jones, C.Hauser-Kronberger, G.Hutarew, R.Reitsamer, R.Jones, M.Dowsett, E.Mueller-Holzner, G.Windbichler, G.Daxenbichler, G.Goebel, C.Ensinger, I.J.Jacobs, M.Widschwendter. Methylated NEUROD1 promoter is a marker for chemonsensitivity in breast cancer. Clin Cancer Res. (2008); 14: 3494-3502.
H.Fiegl, G.Windbichler, E.Mueller-Holzner, G.Goebel, M.Lechner, I.J.Jacobs, M.Widschwendter. HOXA11 DNA methylation – a novel prognostic biomarker in ovarian cancer. Int J Cancer. (2008); 123:725-729.
Akhoondi S, Sun D, von der Lehr N, Apostolidou S, Klotz K, Maljukova A, Cepeda D, Fiegl H, Dafou D, Marth C, Mueller-Holzner E, Corcoran M, Dagnell M, Nejad SZ, Nayer BN, Zali MR, Hansson J, Egyhazi S, Petersson F, Sangfelt P, Nordgren H, Grander D, Reed SI, Widschwendter M, Sangfelt O, Spruck C. FBXW7/hCDC4 is a general tumor suppressor in human cancer. Cancer Res. (2007 Oct 1); 67(19):9006-12.
M.Widschwendter. 5-methylcytosine – the fifth base of DNA: The fifth wheel on a car or a highly promising diagnostic and therapeutic target in cancer? Dis Markers. (2007); 23: 1-3.
M.Widschwendter, H.Fiegl, D.Egle, E.Mueller-Holzner, G.Spizzo, C.Marth, D.J.Weisenberger, M.Campan, J.Young, I.Jacobs, P.W.Laird. Epigenetic stem cell signature in cancer. Nat Genet. (2007); 39:157-158.
M.Widschwendter, U.Menon. Circulating methylated DNA: a new generation of tumor markers. Clin Cancer Res. (2006); 12:7205-7208.
C.Spruck, D.Sun, H.Fiegl, C.Marth, E.Mueller-Holzner, G.Goebel, M.Widschwendter, S.I.Reed. Detection of low molecular weight derivatives of cyclin E1 is a function of cyclin E1 protein levels in breast cancer. Cancer Res. (2006); 66:7355-7360.
D.J.Weisenberger, K.D.Siegmund, M.Campan, J.Young, T.I.Long, M.A.Faasse, G.H.Kang, M.Widschwendter, D.Weener, D.Buchanan, H.Koh, L.Simms, M.Barker, B.Leggett, J.Levine, M.Kim, A.J.French, S.N.Thibodeau, J.Jass, R.Haile, P.W.Laird. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat Genet. (2006); 38:787-793.
H.Fiegl, S.Millinger, G.Goebel, E.Muller-Holzner, C.Marth, P.W.Laird, M.Widschwendter. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. Cancer Res. (2006); 66:29-33.
G.Goebel, H.M.Muller, H.Fiegl, M.Widschwendter. Gene methylation data--a new challenge for bioinformaticians? Methods Inf Med. (2005); 44:516-519.
H.Fiegl, S.Millinger, E.Mueller-Holzner, C.Marth, C.Ensinger, A.Berger, H.Klocker, G.Goebel, M.Widschwendter. Circulating tumor-specific DNA: a marker for monitoring efficacy of adjuvant therapy in cancer patients. Cancer Res. (2005); 65:1141-1145.
K.Jackson, M.C.Yu, K.Arakawa, E.Fiala, B.Youn, H.Fiegl, E.Muller-Holzner, M.Widschwendter, M.Ehrlich. DNA hypomethylation is prevalent even in low-grade breast cancers. Cancer Biol Ther. (2004); 3:1225-1231.
H.M.Muller, S.Millinger, H.Fiegl, G.Goebel, L.Ivarsson, A.Widschwendter, E.Muller-Holzner, C.Marth, M.Widschwendter. Analysis of methylated genes in peritoneal fluids of ovarian cancer patients: a new prognostic tool. Clin Chem. (2004); 50:2171-2173.
B.Rainer, J.Berger, M.Widschwendter, G.Mitterschiffthaler, G.Putz. [Tumorectomy in conscious patient with suspected pregnancy associated breast cancer under cervical epidural anesthesia]. Anasthesiol Intensivmed Notfallmed Schmerzther. (2004); 39:412-414.
H.M.Muller, H.Fiegl, A.Widschwendter, M.Widschwendter. Prognostic DNA methylation marker in serum of cancer patients. Ann N Y Acad Sci. (2004); 1022:44-49.
M.Widschwendter, G.Jiang, C.Woods, H.M.Muller, H.Fiegl, G.Goebel, C.Marth, E.Muller-Holzner, A.G.Zeimet, P.W.Laird, M.Ehrlich. DNA hypomethylation and ovarian cancer biology. Cancer Res. (2004); 64:4472-4480.
M.Widschwendter, K.D.Siegmund, H.M.Muller, H.Fiegl, C.Marth, E.Muller-Holzner, P.A.Jones, P.W.Laird. Association of breast cancer DNA methylation profiles with hormone receptor status and response to tamoxifen. Cancer Res. (2004); 64:3807-3813.
H.M.Muller, L.Ivarsson, H.Schrocksnadel, H.Fiegl, A.Widschwendter, G.Goebel, S.Kilga-Nogler, H.Philadelphy, W.Gutter, C.Marth, M.Widschwendter. DNA methylation changes in sera of women in early pregnancy are similar to those in advanced breast cancer patients. Clin Chem. (2004); 50:1065-1068.
A.Widschwendter, C.Gattringer, L.Ivarsson, H.Fiegl, A.Schneitter, A.Ramoni, H.M.Muller, A.Wiedemair, S.Jerabek, E.Muller-Holzner, G.Goebel, C.Marth, M.Widschwendter. Analysis of aberrant DNA methylation and human papillomavirus DNA in cervicovaginal specimens to detect invasive cervical cancer and its precursors. Clin Cancer Res. (2004); 10:3396-3400.
H.Fiegl, C.Gattringer, A.Widschwendter, A.Schneitter, A.Ramoni, D.Sarlay, I.Gaugg, G.Goebel, H.M.Muller, E.Mueller-Holzner, C.Marth, M.Widschwendter. Methylated DNA collected by tampons--a new tool to detect endometrial cancer. Cancer Epidemiol Biomarkers Prev. (2004); 13:882-888.
H.M.Muller, A.Widschwendter, H.Fiegl, G.Goebel, A.Wiedemair, E.Muller-Holzner, C.Marth, M.Widschwendter. A DNA methylation pattern similar to normal tissue is associated with better prognosis in human cervical cancer. Cancer Lett. (2004); 209:231-236.
A.Widschwendter, H.M.Muller, M.M.Hubalek, A.Wiedemair, H.Fiegl, G.Goebel, E.Mueller-Holzner, C.Marth, M.Widschwendter. Methylation status and expression of human telomerase reverse transcriptase in ovarian and cervical cancer. Gynecol Oncol. (2004); 93:407-416.
H.M.Muller, M.Oberwalder, H.Fiegl, M.Morandell, G.Goebel, M.Zitt, M.Muhlthaler, D.Ofner, R.Margreiter, M.Widschwendter. Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet. (2004); 363:1283-1285.
M.M.Hubalek, A.Widschwendter, M.Erdel, A.Gschwendtner, H.M.Fiegl, H.M.Muller, G.Goebel, E.Mueller-Holzner, C.Marth, C.H.Spruck, S.I.Reed, M.Widschwendter. Cyclin E dysregulation and chromosomal instability in endometrial cancer. Oncogene. (2004); 23:4187-4192.
B.Del Frari, P.Pulzl, T.Schoeller, M.Widschwendter, G.Wechselberger. Pregnancy as a tissue expander in the correction of a scar deformity. Am J Obstet Gynecol. (2004); 190:579-580.
S.Ekholm-Reed, C.H.Spruck, O.Sangfelt, F.van Drogen, E.Mueller-Holzner, M.Widschwendter, A.Zetterberg, S.I.Reed. Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer. Cancer Res. (2004); 64:795-800.
A.Widschwendter, H.M.Muller, H.Fiegl, L.Ivarsson, A.Wiedemair, E.Muller-Holzner, G.Goebel, C.Marth, M.Widschwendter. DNA methylation in serum and tumors of cervical cancer patients. Clin Cancer Res. (2004); 10:565-571.
A.Widschwendter, L.Ivarsson, A.Blassnig, H.M.Muller, H.Fiegl, A.Wiedemair, E.Muller-Holzner, G.Goebel, C.Marth, M.Widschwendter. CDH1 and CDH13 methylation in serum is an independent prognostic marker in cervical cancer patients. Int J Cancer. (2004); 109:163-166.
H.M.Muller, A.Widschwendter, H.Fiegl, L.Ivarsson, G.Goebel, E.Perkmann, C.Marth, M.Widschwendter. DNA methylation in serum of breast cancer patients: an independent prognostic marker. Cancer Res. (2003); 63:7641-7645.
H.M.Muller, H.Fiegl, G.Goebel, M.M.Hubalek, A.Widschwendter, E.Muller-Holzner, C.Marth, M.Widschwendter. MeCP2 and MBD2 expression in human neoplastic and non-neoplastic breast tissue and its association with oestrogen receptor status. Br J Cancer. (2003); 89:1934-1939.
H.M.Muller, M.Widschwendter. Methylated DNA as a possible screening marker for neoplasticdisease in several body fluids. Expert Rev Mol Diagn. (2003); 3:443-458.
M.Ehrlich, G.Jiang, E.Fiala, J.S.Dome, M.C.Yu, T.I.Long, B.Youn, O.S.Sohn, M.Widschwendter, G.E.Tomlinson, M.Chintagumpala, M.Champagne, D.Parham, G.Liang, K.Malik, P.W.Laird. Hypomethylation and hypermethylation of DNA in Wilms tumors. Oncogene. (2002); 21:6694-6702.
C.H.Spruck, H.Strohmaier, O.Sangfelt, H.M.Muller, M.Hubalek, E.Muller-Holzner, C.Marth, M.Widschwendter, S.I.Reed. hCDC4 gene mutations in endometrial cancer. Cancer Res. (2002); 62:4535-4539.
M.Widschwendter, P.A.Jones. DNA methylation and breast carcinogenesis. Oncogene. (2002); 21:5462-5482.
A.G.Zeimet, E.Muller-Holzner, A.Schuler, G.Hartung, J.Berger, M.Hermann, M.Widschwendter, J.M.Bergelson, C.Marth. Determination of molecules regulating gene delivery using adenoviral vectors in ovarian carcinomas. Gene Ther. (2002); 9:1093-1100.
M.Widschwendter, P.A.Jones. The potential prognostic, predictive, and therapeutic values of DNA methylation in cancer. Commentary re: J. Kwong et al., Promoter hypermethylation of multiple genes in nasopharyngeal carcinoma. Clin. Cancer Res., 8: 131-137, 2002, and H-Z. Zou et al., Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin. Cancer Res. 8: 188-191, 2002. Clin Cancer Res. (2002); 8:17-21.
M.Widschwendter, J.Berger, H.M.Muller, A.G.Zeimet, C.Marth. Epigenetic downregulation of the retinoic acid receptor-beta2 gene in breast cancer. J Mammary Gland Biol Neoplasia. (2001); 6:193-201.
A.Amberger, H.Weiss, T.Haller, G.Kock, M.Hermann, M.Widschwendter, R.Margreiter. A subpopulation of mitochondria prevents cytosolic calcium overload in endothelial cells after cold ischemia/reperfusion. Transplantation. (2001); 71:1821-1827.
H.Weiss, A.Amberger, M.Widschwendter, R.Margreiter, D.Ofner, P.Dietl. Inhibition of store-operated calcium entry contributes to the anti-proliferative effect of non-steroidal anti-inflammatory drugs in human colon cancer cells. Int J Cancer. (2001); 92:877-882.
A.G.Zeimet, S.Stadlmann, C.Natoli, M.Widschwendter, M.Hermann, B.Abendstein, G.Daxenbichler, F.A.Offner, S.Iacobelli, C.Marth. Peritoneal mesothelial cells as a significant source of ascitic immunostimulatory protein 90K. Anticancer Res. (2000); 20:4507-4511.
A.M.Bergant, M.Widschwendter, N.Sepp. Bilateral nipple ulcers in a breastfeeding woman: a manifestation of Behcet's disease? BJOG. (2000); 107:1320-1322.
A.G.Zeimet, K.Riha, J.Berger, M.Widschwendter, M.Hermann, G.Daxenbichler, C.Marth. New insights into p53 regulation and gene therapy for cancer. Biochem Pharmacol. (2000); 60:1153-1163.
B.Abendstein, A.Zeimet, M.Rieger, M.Widschwendter, F.Offner, E.Muller-Holzner. Alveolar echinococcosis with bulky peritoneal spread--a rare but important diagnosis in gynaecological practice. BJOG. (2000); 107:695-697.
M.Widschwendter, J.Berger, M.Hermann, H.M.Muller, A.Amberger, M.Zeschnigk, A.Widschwendter, B.Abendstein, A.G.Zeimet, G.Daxenbichler, C.Marth. Methylation and silencing of the retinoic acid receptor-beta2 gene in breast cancer. J Natl Cancer Inst. (2000); 92:826-832.
J.Berger, A.Telser, M.Widschwendter, E.Muller-Holzner, G.Daxenbichler, C.Marth, A.G.Zeimet. Expression of retinoic acid receptors in non-neoplastic epithelial disorders of the vulva and normal vulvar skin. Int J Gynecol Pathol. (2000); 19:95-102.
B.Abendstein, C.Marth, E.Muller-Holzner, M.Widschwendter, G.Daxenbichler, A.G.Zeimet. Clinical significance of serum and ascitic p53 autoantibodies in epithelial ovarian carcinoma. Cancer. (2000); 88:1432-1437.